Genmab | GEN - Gross Profit On Sales


Genmab reported DKK977M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amarin USD 23.17M 961K Dec/2025
Amgen USD 6.89B 415M Dec/2025
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Demant DKK 8.82B 277M Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Fresenius Medical Care EUR 1.18B 210M Mar/2026
Genmab DKK 977M 13M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
GN Store Nord DKK 2.5B 344M Dec/2025
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Insmed USD 256.46M 38.78M Mar/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025